[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Ferno-Washington Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":82},{"warningLetters":4,"total":81},[5,33,58],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},1462,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-05-14T13:20:00Z\">05\u002F14\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-30T04:00:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwashington-fertility-center-678931-04302024\">Washington Fertility Center\u003C\u002Fa>","Division of Biological Products Operations I","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-678931\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pierre Asmar, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Washington Fertility Center\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4316 Evergreen Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Annandale\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22003-2070\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Biological Products Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 30, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Asmar:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Washington Fertility Center, located at 4316 Evergreen Lane, Annandale, VA, between October 11, 2023, and November 2, 2023. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act (42 U.S.C. 264).\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA 483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; Failure to test a specimen from an anonymous or directed reproductive donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]. For example, the donor specimen collected from anonymous oocyte donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>, was not tested for human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) by the nucleic acid test (NAT) method. Oocytes were recovered from this donor on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2.&nbsp; Failure to screen a donor of reproductive cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)]. FDA’s regulations at 21 CFR 1271.3(s) define the term “relevant medical records” to include a current donor medical history interview and a current report of the physical examination of a living donor. For example:\u003C\u002Fp>\n\n\u003Cp>a) The records for directed oocyte donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>&nbsp;lack documentation of a current medical history interview and current report of the physical examination of the donor. Oocytes were recovered from this donor on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>b) Your donor medical history questionnaire, \u003Cem>Donor Medical History Interview Questionnaire\u003C\u002Fem> and \u003Cem>Zika Virus Screening Questionnaire for Oocyte Donors\u003C\u002Fem>, are used as relevant medical records to determine donor eligibility. However, the forms do not include screening for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. For example, questions for the following risk factors for relevant communicable disease agents and disease are incomplete:\u003C\u002Fp>\n\n\u003Cp>i. Question 2 of the \u003Cem>ZIKA Virus Screening Questionnaire for Oocyte Donors\u003C\u002Fem> asks, “Have you resided in or traveled to an area (refer to Zika list, page two) with active Zika virus transmission, in the past 6 months?” This question should ask, “Have you resided in or traveled to an \u003Cu>\u003Cem>area with an increased risk\u003C\u002Fem>\u003C\u002Fu> for ZIKV transmission in the past 6 months?”\u003C\u002Fp>\n\n\u003Cp>ii. The \u003Cem>ZIKA Virus Screening Questionnaire for Oocyte Donors\u003C\u002Fem> lists “Current Zika Affected Areas” as of March 27, 2019. However, this list has not been updated to include all the current ZIKA virus (ZIKV) risk areas around the world.\u003C\u002Fp>\n\n\u003Cp>iii. Question 23 of the \u003Cem>Donor Medical History Interview Questionnaire\u003C\u002Fem> states, “Since 1980, have you ever lived in or traveled to Europe? (includes: Albania, Austria, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Liechtenstein, Luxembourg, Macedonia, Netherlands, Norway, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, and Yugoslavia).” Although the question asks if the donor has ever lived in or traveled to Europe, it is qualified by listing specific countries of travel. The U.K. (England, Scotland, Wales, the Isle of Man, the Channel Islands, Gibraltar, and the Falkland Islands) is not included in this list. If the donor answers “No” to question 23, the questionnaire instructs the donor to skip questions 23 (a-c) pertaining to CJD risk factors within the U.K. (travel and transfusion of blood or blood components).\u003C\u002Fp>\n\n\u003Cp>3. Failure to determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 21 CFR 1271.85 [21 CFR 1271.50(a)]. For example, the eligibility of anonymous oocyte donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined and documented prior to the receipt of the results of donor testing for relevant communicable disease agents. A specimen for communicable disease testing was collected from anonymous oocyte donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on December 7, 2021, but test results were not reported until December 9, 2021.\u003C\u002Fp>\n\n\u003Cp>4. Failure of a responsible person to determine and document the eligibility of a cell or tissue donor [21 CFR 1271.50(a)]. For example:\u003Cbr>\n\u003Cbr>\na) The records for anonymous oocyte donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> (oocyte recovery date: \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>) did not contain any documentation of the donor eligibility determination, which must be based on the results of mandatory donor screening and testing.\u003Cbr>\nb) The records for anonymous oocyte donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> (oocyte recovery date: \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>) did not contain any documentation of the donor eligibility determination, which must be based on the results of mandatory donor screening and testing.\u003Cbr>\nc) The records for anonymous oocyte donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> did not contain documentation that the donor was determined “eligible.” The \u003Cem>Summary of Records\u003C\u002Fem> form for donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> included the name of the responsible person and the date, however the record did not document that the donor was determined eligible.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain procedures for all steps performed in testing, screening, determining donor eligibility, and complying with all other requirements of Subpart C “Donor Eligibility” in 21 CFR Part 1271.45-1271.90. “Establish and maintain” means define, document, and implement; then follow, review, and as needed, revise on an ongoing basis [21 CFR 1271.47(a)]. For example:\u003C\u002Fp>\n\n\u003Cp>a) Your procedures do not include the requirement to screen donors for risk factors for ZIKV.\u003Cbr>\nb) Your procedures do not include HBV NAT as a required test for relevant communicable disease agent and diseases.\u003Cbr>\nc) The current version of your \u003Cem>Donor Medical History Interview Questionnaire\u003C\u002Fem>, used to screen anonymous oocyte donors, was revised on November 17, 2021; however, the previous and obsolete questionnaire (revised on June 1, 2019), was the version included in the current procedure manual and was used to screen at least two donors.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain a procedure governing the release of an HCT\u002FP from a donor whose specimen tests reactive for cytomegalovirus (CMV) [21 CFR 1271.85(b)(2)].\u003Cbr>\nFor example, your procedures do not include how you will communicate test results of donors who are positive or reactive for CMV total antibody, including how the CMV test results should be communicated to the physician responsible for accepting the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all applicable requirements of the federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with all FDA regulatory requirements.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter dated November 10, 2023, which provides a response and corrective actions to FDA’s inspectional observations. We have reviewed the corrective actions outlined in the response and we have determined that they are inadequate to address our concerns. A previous inspection of your facility conducted between October 30, 2018, and November 14, 2018, resulted in the issuance of an Untitled Letter dated May 3, 2019. Despite your commitment to correct the previously noted violations, the current inspection (October 11, 2023 - November 2, 2023) documented some of the same or similar violations, indicating that your corrective actions were either not implemented or were not effective to prevent the recurrence of the previously identified violations. We have serious concerns about your ability to correct the violations noted above and prevent their recurrence.\u003C\u002Fp>\n\n\u003Cp>Your July 13, 2019, response to the Untitled Letter included a corrective action plan that committed to both immediate and preventive corrections such as revisions to forms and procedures. For example:\u003C\u002Fp>\n\n\u003Cp>1. In regard to screening donors for ZIKV, you stated, “Current Zika Virus screening form for Oocyte Donors is currently updated periodically and includes all areas at risk for ZIKA according to the CDC including area within the United States.” Yet the current inspection documented that you are continuing to screen donors with the \u003Cem>ZIKA Virus Screening Questionnaire for Oocyte Donors\u003C\u002Fem> that lists “Current Zika Affected Areas” as of March 27, 2019. Your form was not updated at the time of your response and has not been updated since. The latest update on areas with Zika virus risk from the Centers for Disease Control and Prevention is dated October 11, 2022.\u003C\u002Fp>\n\n\u003Cp>2. Regarding the failure to perform a physical examination for donors, you stated, “The provider shall accurately complete the physical examination. All forms shall immediately be entered into the Donor’s \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Medical Record.” During the current inspection, at least two donors were missing documentation of a physical examination.\u003C\u002Fp>\n\n\u003Cp>3. In regard to establishing and maintaining a procedure for the release of an HCT\u002FP from a donor whose specimen tests reactive for CMV, you stated, “Our procedure now mandates that the release of HCT\u002FPs from all semen donors who test positive for CMV shall have this information appear in materials accompanying the HCT\u002FP so that the physicians can make an informed decision about the use of an HCT\u002FP.” However, the current inspection documented that this procedure was still missing.\u003C\u002Fp>\n\n\u003Cp>4. In the May 3, 2019, Untitled Letter, we noted that our review of your \u003Cem>Procedure Manual for the Washington Fertility Center\u003C\u002Fem> (effective 12\u002F03\u002F13), found requirements that were not in accordance with 21 CFR 1271. For example, the “Donor Testing” section for anonymous donors stated that a positive test for Hepatitis B Surface Antigen (HBsAg), “may not make the donor ineligible.” In accordance with 21 CFR 1271.80(d)(1), a donor whose specimen tests reactive on a screening test for a communicable disease agent in accordance with 21 CFR 1271.85 must be determined to be ineligible. This applies to both anonymous and directed donors.\u003C\u002Fp>\n\n\u003Cp>Additionally, the section discussing testing for directed donors states that positive results for the relevant communicable diseases listed “would require special labeling of HCT\u002FP.” While special labeling is required for such donors under 21 CFR 1271.65(b)(2), we note that your procedure does not require that directed donors with positive test results for a relevant communicable disease agent be determined ineligible.\u003C\u002Fp>\n\n\u003Cp>Our review of your \u003Cem>HCT\u002FPs Procedure Manual v. 3.0\u003C\u002Fem>, revised in February 2021 and in use during the current inspection, noted that these two requirements related to anonymous and directed donor testing had not been updated since the issuance of the Untitled Letter.\u003Cbr>\n\u003Cbr>\nWe recommend that you review your firm’s procedures and make the necessary changes to ensure they include all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of subpart C - Donor Eligibility.\u003C\u002Fp>\n\n\u003Cp>Additionally, we have the following comments regarding your November 10, 2023, FDA 483 response and your firm’s corrective actions to the most recent inspection of your establishment.\u003C\u002Fp>\n\n\u003Cp>1. We want to remind you of the labeling requirements for HCT\u002FPs from donors for whom a donor eligibility determination is not required under 21 CFR 1271.90(a) and (b). Please note that such HCT\u002FPs must be labeled in accordance with 21 CFR 1271.90(c).\u003C\u002Fp>\n\n\u003Cp>2. Regarding the documentation of the donor eligibility determination, please note that in accordance with 21 CFR 1271.50(a), a responsible person must determine and document the eligibility of a cell or tissue donor. In accordance with 21 CFR 1271.55(d)(1)(iii), such documentation must include the name of the responsible person who makes the determination and the date of the determination. Under 21 CFR 1271.55(d)(2), all records must be accurate, indelible, and legible. If you designate more than one responsible person for such purposes, the donor eligibility determination documentation should reflect the person making the determination.\u003C\u002Fp>\n\n\u003Cp>Please note that if you still have \u003Cstrong>oocytes and\u002For semen\u003C\u002Fstrong> in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were not appropriately tested for relevant communicable disease agents and diseases (i.e., HIV-1\u002FHCV\u002FHBV NAT) and\u002For who were not appropriately screened for relevant communicable disease risk factors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\u003C\u002Fp>\n\n\u003Cp>Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in Subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at Exemptions and Alternatives | FDA. The email address for submissions is HCTPExemptions@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\u003C\u002Fp>\n\n\u003Cp>If you still have \u003Cstrong>embryos\u003C\u002Fstrong> in storage for which the donor eligibility requirements under 21 CFR 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine (21 CFR 1271.90(b)) provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to Alice Silva, Compliance Officer at the following email address: Alice.Silva@fda.hhs.gov. If you should have any questions, please contact Alice Silva, Compliance Officer via email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision 1 - Office of Biological Products Operations\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\n24-678931\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nPierre Asmar, M.D.\n\nRecipient Title\n\nPresident and Medical Director\n\nWashington Fertility Center\n\n4316 Evergreen Lane\n\nAnnandale, VA 22003-2070\n\nUnited States\n\nIssuing Office:\n\nDivision of Biological Products Operations I\n\nUnited States\n\nWARNING LETTER\n\nApril 30, 2024\n\nDear Dr. Asmar:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Washington Fertility Center, located at 4316 Evergreen Lane, Annandale, VA, between October 11, 2023, and November 2, 2023. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act (42 U.S.C. 264).\n\nThe deviations documented on the Form FDA 483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\n\n1. Failure to test a specimen from an anonymous or directed reproductive donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]. For example, the donor specimen collected from anonymous oocyte donor (b)(6), (b)(7)(C) on (b)(6), (b)(7)(C), was not tested for human immunodeficiency virus, type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) by the nucleic acid test (NAT) method. Oocytes were recovered from this donor on (b)(6), (b)(7)(C).\n\n2. Failure to screen a donor of reproductive cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)]. FDA’s regulations at 21 CFR 1271.3(s) define the term “relevant medical records” to include a current donor medical history interview and a current report of the physical examination of a living donor. For example:\n\na) The records for directed oocyte donor (b)(6), (b)(7)(C) lack documentation of a current medical history interview and current report of the physical examination of the donor. Oocytes were recovered from this donor on (b)(6), (b)(7)(C).\n\nb) Your donor medical history questionnaire, Donor Medical History Interview Questionnaire and Zika Virus Screening Questionnaire for Oocyte Donors, are used as relevant medical records to determine donor eligibility. However, the forms do not include screening for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. For example, questions for the following risk factors for relevant communicable disease agents and disease are incomplete:\n\ni. Question 2 of the ZIKA Virus Screening Questionnaire for Oocyte Donors asks, “Have you resided in or traveled to an area (refer to Zika list, page two) with active Zika virus transmission, in the past 6 months?” This question should ask, “Have you resided in or traveled to an area with an increased risk for ZIKV transmission in the past 6 months?”\n\nii. The ZIKA Virus Screening Questionnaire for Oocyte Donors lists “Current Zika Affected Areas” as of March 27, 2019. However, this list has not been updated to include all the current ZIKA virus (ZIKV) risk areas around the world.\n\niii. Question 23 of the Donor Medical History Interview Questionnaire states, “Since 1980, have you ever lived in or traveled to Europe? (includes: Albania, Austria, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Liechtenstein, Luxembourg, Macedonia, Netherlands, Norway, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, and Yugoslavia).” Although the question asks if the donor has ever lived in or traveled to Europe, it is qualified by listing specific countries of travel. The U.K. (England, Scotland, Wales, the Isle of Man, the Channel Islands, Gibraltar, and the Falkland Islands) is not included in this list. If the donor answers “No” to question 23, the questionnaire instructs the donor to skip questions 23 (a-c) pertaining to CJD risk factors within the U.K. (travel and transfusion of blood or blood components).\n\n3. Failure to determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 21 CFR 1271.85 [21 CFR 1271.50(a)]. For example, the eligibility of anonymous oocyte donor (b)(6), (b)(7)(C) was determined and documented prior to the receipt of the results of donor testing for relevant communicable disease agents. A specimen for communicable disease testing was collected from anonymous oocyte donor (b)(6), (b)(7)(C) on (b)(6), (b)(7)(C). Donor (b)(6), (b)(7)(C) was determined eligible on December 7, 2021, but test results were not reported until December 9, 2021.\n\n4. Failure of a responsible person to determine and document the eligibility of a cell or tissue donor [21 CFR 1271.50(a)]. For example:\n\na) The records for anonymous oocyte donor (b)(6), (b)(7)(C) (oocyte recovery date: (b)(6), (b)(7)(C)) did not contain any documentation of the donor eligibility determination, which must be based on the results of mandatory donor screening and testing.\n\nb) The records for anonymous oocyte donor (b)(6), (b)(7)(C) (oocyte recovery date: (b)(6), (b)(7)(C)) did not contain any documentation of the donor eligibility determination, which must be based on the results of mandatory donor screening and testing.\n\nc) The records for anonymous oocyte donor (b)(6), (b)(7)(C) did not contain documentation that the donor was determined “eligible.” The Summary of Records form for donor (b)(6), (b)(7)(C) included the name of the responsible person and the date, however the record did not document that the donor was determined eligible.\n\n5. Failure to establish and maintain procedures for all steps performed in testing, screening, determining donor eligibility, and complying with all other requirements of Subpart C “Donor Eligibility” in 21 CFR Part 1271.45-1271.90. “Establish and maintain” means define, document, and implement; then follow, review, and as needed, revise on an ongoing basis [21 CFR 1271.47(a)]. For example:\n\na) Your procedures do not include the requirement to screen donors for risk factors for ZIKV.\n\nb) Your procedures do not include HBV NAT as a required test for relevant communicable disease agent and diseases.\n\nc) The current version of your Donor Medical History Interview Questionnaire, used to screen anonymous oocyte donors, was revised on November 17, 2021; however, the previous and obsolete questionnaire (revised on June 1, 2019), was the version included in the current procedure manual and was used to screen at least two donors.\n\n6. Failure to establish and maintain a procedure governing the release of an HCT\u002FP from a donor whose specimen tests reactive for cytomegalovirus (CMV) [21 CFR 1271.85(b)(2)].\n\nFor example, your procedures do not include how you will communicate test results of donors who are positive or reactive for CMV total antibody, including how the CMV test results should be communicated to the physician responsible for accepting the HCT\u002FP.\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all applicable requirements of the federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with all FDA regulatory requirements.\n\nWe acknowledge receipt of your letter dated November 10, 2023, which provides a response and corrective actions to FDA’s inspectional observations. We have reviewed the corrective actions outlined in the response and we have determined that they are inadequate to address our concerns. A previous inspection of your facility conducted between October 30, 2018, and November 14, 2018, resulted in the issuance of an Untitled Letter dated May 3, 2019. Despite your commitment to correct the previously noted violations, the current inspection (October 11, 2023 - November 2, 2023) documented some of the same or similar violations, indicating that your corrective actions were either not implemented or were not effective to prevent the recurrence of the previously identified violations. We have serious concerns about your ability to correct the violations noted above and prevent their recurrence.\n\nYour July 13, 2019, response to the Untitled Letter included a corrective action plan that committed to both immediate and preventive corrections such as revisions to forms and procedures. For example:\n\n1. In regard to screening donors for ZIKV, you stated, “Current Zika Virus screening form for Oocyte Donors is currently updated periodically and includes all areas at risk for ZIKA according to the CDC including area within the United States.” Yet the current inspection documented that you are continuing to screen donors with the ZIKA Virus Screening Questionnaire for Oocyte Donors that lists “Current Zika Affected Areas” as of March 27, 2019. Your form was not updated at the time of your response and has not been updated since. The latest update on areas with Zika virus risk from the Centers for Disease Control and Prevention is dated October 11, 2022.\n\n2. Regarding the failure to perform a physical examination for donors, you stated, “The provider shall accurately complete the physical examination. All forms shall immediately be entered into the Donor’s (b)(4) Medical Record.” During the current inspection, at least two donors were missing documentation of a physical examination.\n\n3. In regard to establishing and maintaining a procedure for the release of an HCT\u002FP from a donor whose specimen tests reactive for CMV, you stated, “Our procedure now mandates that the release of HCT\u002FPs from all semen donors who test positive for CMV shall have this information appear in materials accompanying the HCT\u002FP so that the physicians can make an informed decision about the use of an HCT\u002FP.” However, the current inspection documented that this procedure was still missing.\n\n4. In the May 3, 2019, Untitled Letter, we noted that our review of your Procedure Manual for the Washington Fertility Center (effective 12\u002F03\u002F13), found requirements that were not in accordance with 21 CFR 1271. For example, the “Donor Testing” section for anonymous donors stated that a positive test for Hepatitis B Surface Antigen (HBsAg), “may not make the donor ineligible.” In accordance with 21 CFR 1271.80(d)(1), a donor whose specimen tests reactive on a screening test for a communicable disease agent in accordance with 21 CFR 1271.85 must be determined to be ineligible. This applies to both anonymous and directed donors.\n\nAdditionally, the section discussing testing for directed donors states that positive results for the relevant communicable diseases listed “would require special labeling of HCT\u002FP.” While special labeling is required for such donors under 21 CFR 1271.65(b)(2), we note that your procedure does not require that directed donors with positive test results for a relevant communicable disease agent be determined ineligible.\n\nOur review of your HCT\u002FPs Procedure Manual v. 3.0, revised in February 2021 and in use during the current inspection, noted that these two requirements related to anonymous and directed donor testing had not been updated since the issuance of the Untitled Letter.\n\nWe recommend that you review your firm’s procedures and make the necessary changes to ensure they include all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of subpart C - Donor Eligibility.\n\nAdditionally, we have the following comments regarding your November 10, 2023, FDA 483 response and your firm’s corrective actions to the most recent inspection of your establishment.\n\n1. We want to remind you of the labeling requirements for HCT\u002FPs from donors for whom a donor eligibility determination is not required under 21 CFR 1271.90(a) and (b). Please note that such HCT\u002FPs must be labeled in accordance with 21 CFR 1271.90(c).\n\n2. Regarding the documentation of the donor eligibility determination, please note that in accordance with 21 CFR 1271.50(a), a responsible person must determine and document the eligibility of a cell or tissue donor. In accordance with 21 CFR 1271.55(d)(1)(iii), such documentation must include the name of the responsible person who makes the determination and the date of the determination. Under 21 CFR 1271.55(d)(2), all records must be accurate, indelible, and legible. If you designate more than one responsible person for such purposes, the donor eligibility determination documentation should reflect the person making the determination.\n\nPlease note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were not appropriately tested for relevant communicable disease agents and diseases (i.e., HIV-1\u002FHCV\u002FHBV NAT) and\u002For who were not appropriately screened for relevant communicable disease risk factors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\n\nShould the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in Subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at Exemptions and Alternatives | FDA. The email address for submissions is HCTPExemptions@fda.hhs.gov.\n\nPlease note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\n\nIf you still have embryos in storage for which the donor eligibility requirements under 21 CFR 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine (21 CFR 1271.90(b)) provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\n\nYour response should be sent to Alice Silva, Compliance Officer at the following email address: Alice.Silva@fda.hhs.gov. If you should have any questions, please contact Alice Silva, Compliance Officer via email.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nDivision 1 - Office of Biological Products Operations","Washington Fertility Center","washington-fertility-center-678931-04302024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwashington-fertility-center-678931-04302024","2026-10-26T08:10:30.572265+00:00","Warning Letter","Issued","2024-05-14","678931","Biologics","Pierre Asmar, M.D.","2026-08-20T00:06:20.687+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","24-678931","2024-04-30",{"id":34,"raw":35,"subject":40,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":53,"issuing_office":39,"recipient_name":54,"body_fetched_at":55,"delivery_method":56,"recipient_title":20,"reference_number":20,"action_taken_date":57,"medical_device_id":20,"response_letter_date":20},401,[36,37,38,39,40,13,41,13],"\u003Ctime datetime=\"2025-12-18T16:00:00Z\">12\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarli-washington-design-llc-720840-12162025\">Marli Washington Design, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Failure to Register and List\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarli-washington-design-llc-720840-03272026\">\u003Ctime datetime=\"2026-04-02T04:00:00Z\">04\u002F02\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Marli Washington\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Marli Washington Design, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2502 Harford Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baltimore\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21218\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:legal@gc2b.info\"> legal@gc2b.info\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS #720840\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>December 16, 2025\u003C\u002Fp>\u003Cp>\u003Cbr>Dear Marli Washington:\u003Cbr>\u003Cbr>The United States Food and Drug Administration (FDA) has reviewed Marli Washington Design, LLC d\u002Fb\u002Fa gc2b’s (“your firm”) website (gc2b.co) and observed that your website offers various breast binders for sale. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our review of your firm’s website revealed statements that these breast binders (example trade names: “Black Half Binder (Classic 2.0)”, “Black Tank Binder (Classic 2.0)”, “White Half Binder (Classic 2.0)”, “White Tank Binder (Classic 2.0)”, “Nude No. 5 Half Binder (Classic 2.0)”, “2b Luxe White Racerback”, “2b Luxe Black Half”) are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, including:\u003C\u002Fp>\u003Cp>•&nbsp;&nbsp;&nbsp;&nbsp;Per your firm’s website: “our product is aimed at helping to relieve dysphoria for trans folks”\u003C\u002Fp>\u003Cp>Our review also revealed statements that you manufacture these devices within the meaning of section 510 of the Act (21 U.S.C. § 360) (e.g., “Our founder, CEO, and designer . . . .”; “Using his background in Industrial Design and expertise in textiles . . . .”; “The result was the first binder designed and patented specifically for gender-affirming chest binding.”). Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. &nbsp;In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. &nbsp;Our records indicate that you have not registered or listed these devices for fiscal year 2026.\u003C\u002Fp>\u003Cp>Therefore the devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that they were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. &nbsp;Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. &nbsp;These actions include, but are not limited to, seizure and injunction. &nbsp;\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.&nbsp;\u003Cbr>\u003Cbr>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. &nbsp;Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. &nbsp;If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. &nbsp;If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS 720840” when replying.&nbsp;\u003Cbr>\u003Cbr>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance. &nbsp; &nbsp;\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002Fs\u002F\u003Cbr>Michael J. Hoffmann\u003Cbr>Director\u003Cbr>Office of Health Technology 3 - Gastrorenal, ObGyn,\u003Cbr>General Hospital, and Urology Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>Food and Drug Administration\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Spotify, Inc.: abuse@spotify.com, abuse@gc2b.co, support@gc2b.co\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMarli Washington\n\nRecipient Title\n\nManager\n\nMarli Washington Design, LLC\n\n2502 Harford Rd\n\nBaltimore, MD 21218\n\nUnited States\n\nlegal@gc2b.info\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS #720840\n\nDecember 16, 2025\n\nDear Marli Washington:\n\nThe United States Food and Drug Administration (FDA) has reviewed Marli Washington Design, LLC d\u002Fb\u002Fa gc2b’s (“your firm”) website (gc2b.co) and observed that your website offers various breast binders for sale. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur review of your firm’s website revealed statements that these breast binders (example trade names: “Black Half Binder (Classic 2.0)”, “Black Tank Binder (Classic 2.0)”, “White Half Binder (Classic 2.0)”, “White Tank Binder (Classic 2.0)”, “Nude No. 5 Half Binder (Classic 2.0)”, “2b Luxe White Racerback”, “2b Luxe Black Half”) are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, including:\n• Per your firm’s website: “our product is aimed at helping to relieve dysphoria for trans folks”\nOur review also revealed statements that you manufacture these devices within the meaning of section 510 of the Act (21 U.S.C. § 360) (e.g., “Our founder, CEO, and designer . . . .”; “Using his background in Industrial Design and expertise in textiles . . . .”; “The result was the first binder designed and patented specifically for gender-affirming chest binding.”). Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. Our records indicate that you have not registered or listed these devices for fiscal year 2026.\nTherefore the devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that they were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure and injunction.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS 720840” when replying.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002Fs\u002F\nMichael J. Hoffmann\nDirector\nOffice of Health Technology 3 - Gastrorenal, ObGyn,\nGeneral Hospital, and Urology Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nFood and Drug Administration\n\nSpotify, Inc.: abuse@spotify.com, abuse@gc2b.co, support@gc2b.co","Marli Washington Design, LLC","marli-washington-design-llc-720840-12162025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarli-washington-design-llc-720840-12162025","2026-10-26T08:09:20.803778+00:00","Closed Out","2025-12-18","720840","Medical Devices","2026-04-02","Marli Washington","2026-08-19T07:21:05.364+00:00","VIA Electronic Mail","2025-12-16",{"id":59,"raw":60,"subject":66,"body_html":67,"body_text":68,"firm_name":69,"letter_id":70,"created_at":71,"fei_number":20,"letter_url":72,"updated_at":73,"action_type":23,"case_status":24,"posted_date":74,"marcs_cms_no":75,"product_type":76,"closeout_date":20,"issuing_office":64,"recipient_name":77,"body_fetched_at":78,"delivery_method":79,"recipient_title":20,"reference_number":20,"action_taken_date":80,"medical_device_id":20,"response_letter_date":20},2143,[61,62,63,64,65,13,13,13],"\u003Ctime datetime=\"2023-03-28T13:20:00Z\">03\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-14T04:00:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023\">Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Bioresearch Monitoring Program\u002FIRB ","Bioresearch Monitoring Program\u002FIRB","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert J. Hayashi, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>660 South Euclid Avenue, Box 8116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63110-1010\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ref.: 23-HFD-45-03-02\u003Cbr>\n\u003Cbr>\nDear Dr. Hayashi:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>, of investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>requires that you omit certain \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatments for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the investigational plan for Protocol&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\u003C\u002Fp>\n\n\u003Cp>1. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires that you omit administration of Day 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the final 2 cycles of maintenance therapy for subjects randomized into the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> was a pediatric subject (5 years old) randomized to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, this subject was administered 12 mg of \u003Cstrong>(b)(4)\u003C\u002Fstrong> on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on \u003Cstrong>(b)(6)\u003C\u002Fstrong>, respectively. As a result, this subject underwent invasive procedures associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered \u003Cstrong>(b)(4)\u003C\u002Fstrong> are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an increased risk of infection associated with lumbar punctures.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\u003C\u002Fp>\n\n\u003Cp>You also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> from Day 1 of Cycles 5 and 6 for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reinforcing the need to calculate the end of therapy and when the last administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for \u003Cstrong>(b)(6)&nbsp;\u003C\u002Fstrong>ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong> administration, and that training on these SOPs was provided.\u003C\u002Fp>\n\n\u003Cp>2. The investigational plan for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires an \u003Cstrong>(b)(4)\u003C\u002Fstrong> before the initiation of any cycle of 3-day interval of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)\u003C\u002Fstrong>) administration. If this treatment eligibility criterion is not met, the 3-day course of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) is not initiated. Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong> had a calculated \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(6)\u003C\u002Fstrong>; however, this subject received a 3-day course of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) on Days 1 to 3 of Cycle 3 (\u003Cstrong>(b)(6)\u003C\u002Fstrong>). Thus, you failed to ensure that the only enrolled subject in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Subject \u003Cstrong>(b)(6)\u003C\u002Fstrong>, met the required treatment eligibility criterion before the administration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\u003C\u002Fp>\n\n\u003Cp>As described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\u003C\u002Fp>\n\n\u003Cp>Additionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational \u003Cstrong>(b)(6)\u003C\u002Fstrong> agent; (2) the creation of procedural SOPs for \u003Cstrong>(b)(6)\u003C\u002Fstrong> ordering, to minimize errors in \u003Cstrong>(b)(6)\u003C\u002Fstrong>, with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and (4) good clinical practice training.\u003C\u002Fp>\n\n\u003Cp>We acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\u003C\u002Fp>\n\n\u003Cp>We emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n03\u002F14\u002F2023 07:42:17 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert J. Hayashi, M.D.\n\nRobert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics\n\n660 South Euclid Avenue, Box 8116\n\nSaint Louis, MO 63110-1010\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nRef.: 23-HFD-45-03-02\n\nDear Dr. Hayashi:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your clinical site between June 23, 2022, and July 8, 2022. Investigator Carmen Y. Fisher, representing FDA, reviewed your conduct of the following clinical investigations:\n\nProtocol (b)(4), “(b)(4),” of the investigational drug (b)(4), performed for the (b)(4)\n\nProtocol (b)(4), “(b)(4), of investigational drug (b)(4) performed for the (b)(4)\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Fisher presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your July 28, 2022, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your July 28, 2022, written response, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 [21 CFR 312] governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\n\nYou failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].\n\nAs a clinical investigator, you are required to ensure that your clinical studies are conducted in accordance with the investigational plan. The investigational plan for Protocol (b)(4) requires that you omit certain (b)(4) treatments for subjects randomized into the (b)(4). In addition, the investigational plan for Protocol (b)(4) requires you to ensure that subjects meet certain treatment eligibility criteria before each treatment cycle. You failed to adhere to these requirements. Specifically:\n\n1. The investigational plan for Protocol (b)(4) requires that you omit administration of Day 1 (b)(4) during the final 2 cycles of maintenance therapy for subjects randomized into the (b)(4). Subject (b)(6) was a pediatric subject (5 years old) randomized to the (b)(4); however, this subject was administered 12 mg of (b)(4) on Day 1 of the subject’s final two cycles of maintenance therapy (Cycles 5 and 6), on (b)(6), respectively. As a result, this subject underwent invasive procedures associated with (b)(4) administration, including lumbar punctures for the collection of cerebrospinal fluid and the use of general and local anesthesia. Subjects administered (b)(4) are exposed to an increased risk of neurotoxicity (for example, seizures and encephalopathies) associated with (b)(4), and an increased risk of infection associated with lumbar punctures.\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledged the observation, stating that you take full responsibility for this deviation. You stated that once the error was brought to your attention on February 8, 2022, you notified the subject’s mother, the study chair, and the National Cancer Institute, Pediatric Central IRB (Pediatric CIRB). You stated that the subject experienced no adverse events resulting from the additional doses of (b)(4) and lumbar punctures. You also created and began implementing a Corrective and Preventive Action Plan (CAPA).\n\nYou also stated that you assembled a team, the Clinical Trials Command Center (CTCC), which includes members of the clinical trials task force, the Quality and Safety Committee, and divisional leadership, to field prompt notifications of challenges to your clinical operations as they relate to clinical trial conduct on a weekly basis, and to formulate strategies and actions to eliminate difficulties to prevent errors and optimize patient safety. You described protocol-specific actions that the CTCC has implemented and will monitor. For example, updates to the electronic medical record (EMR) ordering system were made to remove (b)(4) from Day 1 of Cycles 5 and 6 for (b)(4), in anticipation that the end of therapy will be in proximity to these cycles, and therefore subjects will not receive (b)(4).\n\nFurthermore, you stated that you contacted the Children’s Oncology Group (COG) Quality Assurance Office and the study chairs, and that you shared suggestions for a protocol amendment that could raise awareness of this issue, to minimize any recurrence of this event at your center and other centers. You also stated that education was provided to the study staff caring for patients on Protocol (b)(4), reinforcing the need to calculate the end of therapy and when the last administration of (b)(4) is planned. Additionally, you stated that procedural standard operating procedures (SOPs) were created for (b)(6) ordering, to minimize errors in (b)(6) administration, and that training on these SOPs was provided.\n\n2. The investigational plan for Protocol (b)(4) requires an (b)(4) before the initiation of any cycle of 3-day interval of (b)(4) ((b)(4)) administration. If this treatment eligibility criterion is not met, the 3-day course of (b)(4) ((b)(4)) is not initiated. Subject (b)(6) had a calculated (b)(4) on (b)(6); however, this subject received a 3-day course of (b)(4) ((b)(4)) on Days 1 to 3 of Cycle 3 ((b)(6)). Thus, you failed to ensure that the only enrolled subject in Protocol (b)(4), Subject (b)(6), met the required treatment eligibility criterion before the administration of (b)(4).\n\nIn your July 28, 2022, written response to the Form FDA 483, you acknowledge the observation, stating that you take full responsibility for this deviation. You explained that a provider examining the subject had mistakenly understood the protocol to require an (b)(4) for the initiation of a cycle, and this provider had authorized the study drug to be dispensed.\n\nAs described above, you stated that you created and began implementing a CAPA. Corrective actions included notifying the subject’s family and the study chair. You also stated that the subject was monitored for toxicity, and that there were no identifiable significant adverse events associated with this error.\n\nAdditionally, you stated that preventative actions include: (1) the initiation of a “double check” system, in which a nurse and a provider check the drug and dose before dispensing an oral investigational (b)(6) agent; (2) the creation of procedural SOPs for (b)(6) ordering, to minimize errors in (b)(6), with training on these SOPs; (3) education for providers and nurse coordinators on the calculation of (b)(4); and (4) good clinical practice training.\n\nWe acknowledge the corrective and preventive actions that your site has taken and plans to take. However, given the significance of the protocol deviations involving pediatric subjects, we request documentation following up on some of the trainings you listed in your CAPA. For example, you stated in your CAPA that you were going to provide mandatory training by August 15, 2022, to all study personnel who participate in the management of clinical trials subject to an IND. We request that you submit documentation that this training occurred, and that you explain how this training will ensure that ongoing and future clinical investigations will be conducted in compliance with applicable FDA regulations. We cannot undertake an informed evaluation of your written response until you submit this information.\n\nWe emphasize that as the clinical investigator, it is your responsibility to ensure that studies are conducted in accordance with the investigational plan, to protect the rights, safety, and welfare of subjects and to ensure the integrity of study data. Your failure to conduct the clinical study in accordance with the protocol resulted in the unnecessary administration of intrathecal methotrexate and the performance of invasive procedures, such as lumbar punctures and the sedation of a pediatric subject; and the initiation of study treatment cycles for a subject, despite that subject’s not meeting the treatment eligibility criterion. This conduct raises significant concerns about your protection of the study subjects enrolled at your site, and also raises concerns about the validity and integrity of the data collected at your site.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future.\n\nFailure to adequately address this matter may lead to regulatory action. If you believe you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n03\u002F14\u002F2023 07:42:17 AM","Robert J. Hayashi, M.D.\u002FWashington University School of Medicine, Department of Pediatrics","robert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-j-hayashi-mdwashington-university-school-medicine-department-pediatrics-654873-03142023","2026-10-26T08:09:50.433203+00:00","2023-03-28","654873","Drugs","Robert J. Hayashi, M.D.","2026-08-20T01:10:40.684+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2023-03-14",3,{"510k":83,"classification":84,"enforcement":85,"event":86,"event_backfill":87,"pma":88,"warning_letter":89},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]